BRCA2 and ovarian cancer: In contrast, hybrid-capture-based panels have more flexibility in increasing scale or sequencing depth, produce less background noise due to their ability to capture specific target regions, have a higher sensitivity for copy-number changes (such as deletions in the BRCA1 and BRCA2 genes in prostate and ovarian cancer patients), and often utilize ctDNA rather than cfRNA for the detection of fusions, rendering them potentially more sensitive for fusion detection with currently available technology.